Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline...
Neuroscience
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2...
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeingMALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE...
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology...
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the...
KOL Event on Next-Generation Neurotherapeutics: Leveraging the Power of Music and Technology
March 20, 2023 at 11:00 AM ETPORTLAND, Maine, March 08, 2023 (GLOBE NEWSWIRE) -- MedRhythms today announced it will host...
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over...
Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Company Launches a New Educational Campaign For ProvidersMALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s...
BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase...
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced TherapyMALVERN, Pa.,...
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU1...